

Living with ocular (eye-only) myasthenia gravis?

We seek the support of people living with **ocular (eye-only) myasthenia gravis** for the **MyVision Study**.

We also understand that some people living with ocular myasthenia gravis (oMG) may have someone supporting them, so if you or someone you know has oMG, we would like to hear from you.

Ocular myasthenia gravis is a condition that can cause double vision, droopy eyelids, fatigue, light sensitivity, or difficulty looking in different directions. These symptoms can make everyday activities challenging like driving, reading, and watching television, even if you are already on treatment.

The MyVision Study is testing a study drug to see the effects on eye-only symptoms in adults with ocular myasthenia gravis (oMG). The study is hoping to better understand oMG and its symptoms while advancing scientific research at the same time. The aim of the study is to learn how well the study drug works (efficacy) and what side effects people experience while taking it (safety).

You may be able to join the MyVision Study if you:



Are at least 18 years of age



Have been diagnosed with oMG by a doctor



Are **not** experiencing weakness in other muscles in your body such as your face, throat, arms, and/or legs

There are other requirements for taking part in this study, which the study team will discuss with you.

If you qualify and decide to join, you will get:

- The study drug or a placebo (a placebo is similar to the study drug but contains no medically-active ingredient)
- Close medical care and follow-up throughout the study

Reimbursement for travel and other study-related expenses may be provided.

There is an extension study called MyVisionXT that MyVision participants may have an opportunity to join. In the MyVisionXT study, all participants will receive the study drug—there is no chance of receiving a placebo.

If you are interested in taking part in the MyVision Study, please visit myvisionstudy.com or contact the study team to learn more:



 Inspired by patients.
Driven by science.